CFTR Variants of Varying Clinical Consequence Show Wide Penetrance Range in CRMS/CFSPID Infants

MacKenzie L Wyatt, Karen S Raraigh, Anna V Faino, et al.

Summary: This meta-analysis of 25 published studies (606 children total) examined whether specific CFTR variants of varying clinical consequence (VVCCs) differ in their probability of causing diagnostic transition from CRMS/CFSPID to cystic fibrosis. Among the 268 children carrying one VVCC paired with one CF-causing variant, 28% ultimately converted to a CF diagnosis. Penetrance varied substantially by specific variant: some (5T;TG13, Q1476X, P5L) carried ≥50% conversion risk, while others (R117H;7T, D1270N, F1052V) carried considerably lower risk. Elevated sweat chloride was the most common clinical feature observed at the time of conversion.

Why it matters: CRMS/CFSPID represents a genuine clinical challenge born of the success of newborn screening — identifying infants who may or may not develop CF, generating significant family anxiety and uncertain clinical trajectories. Knowing that specific VVCCs confer meaningfully different conversion risks gives clinicians and genetic counselors a more granular, variant-level framework for counseling rather than treating all VVCCs as interchangeable. The findings also have direct policy relevance: decisions about which CFTR variants to include in newborn screening panels have downstream consequences for the volume and composition of the CRMS/CFSPID population, and variant-specific risk data can sharpen those inclusion criteria.

Expert perspective: This is a carefully framed meta-analysis addressing a real and underserved question, and its clinical usefulness is genuine — but several methodological limitations temper confidence in the specific numeric estimates. The fundamental constraint is the aggregate sample size: while 606 children is substantial for a rare condition, once the data are stratified by individual VVCC, most variant-specific estimates rest on very small denominators. Confidence intervals around the reported penetrance figures for individual variants are presumably wide, though the abstract does not present them explicitly — a notable omission. Readers should be cautious about treating point estimates such as "≥50% conversion" for 5T;TG13 or "low risk" for R117H;7T as definitive, as these numbers may shift materially with additional cases.

The meta-analytic approach introduces further complications. Pooling across 25 manuscripts spanning different countries, time periods, diagnostic criteria, and follow-up durations creates substantial heterogeneity. CRMS/CFSPID diagnostic thresholds differ between US and international settings, which could affect who is counted at baseline and who counts as "converted." Follow-up duration is a particularly important variable: a child classified as non-converted at age two might convert at age five, making shorter-follow-up studies systematically undercount true penetrance. Selection bias is also plausible, as published cohorts may overrepresent children with more symptomatic presentations or those followed at specialized CF centers with higher clinical vigilance. None of these limitations negate the work's value. The qualitative signal — that penetrance varies substantially across VVCCs — is almost certainly real even if the precise estimates are uncertain. The finding that elevated sweat chloride is the dominant conversion signal also reinforces the continued centrality of sweat testing in CRMS/CFSPID follow-up. Replication in prospective, standardized registries with harmonized follow-up protocols would meaningfully strengthen these variant-specific estimates.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42629235/

---